GKWIM
ABCL icon

Gerber Kawasaki Wealth & Investment Management’s AbCellera Biologics ABCL Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-500
Closed -$10K – 281
2021
Q3 		$10K Buy
+500
New +$8.84K ﹤0.01% 624

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DB
DCVC Bio Palo Alto, California $313K AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's ABCL Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of AbCellera Biologics (ABCL) in Q4 2021, closing a stake of 500 shares — an estimated $10K sold.

Gerber Kawasaki Wealth & Investment Management first reported a position in ABCL in Q3 2021 and held it in 1 quarter. The position peaked at $10K in Q3 2021. 124 funds tracked by Wall St. Rank hold ABCL as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining AbCellera Biologics position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 500 AbCellera Biologics shares in Q4 2021, an estimated $10K.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in AbCellera Biologics in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's AbCellera Biologics position peaked at $10K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.